Table 1 Baseline demographic characteristics and laboratory values of EVT patients
|  | Overall N = 336 | Active Cancer N = 39 | Non-Active Cancer N = 297 | p-value |
|---|---|---|---|---|
Sex | Â | Â | Â | 0.49 |
 Female | 194 (58%) | 25 (64%) | 169 (57%) |  |
 Male | 142 (42%) | 14 (36%) | 128 (43%) |  |
Age* | 75 (14) | 73 (12) | 76 (14) | 0.10 |
Hypertension | 273 (81%) | 32 (82%) | 241 (81%) | > 0.99 |
Diabetes | 72 (21%) | 11 (28%) | 61 (21%) | 0.30 |
Stroke History | 63 (19%) | 10 (26%) | 53 (18%) | 0.27 |
Cancer History | 38 (11%) | 8 (21%) | 30 (10%) | 0.062 |
Prophylaxis at Admission | Â | Â | Â | 0.065 |
 Antiplatelet | 96 (29%) | 10 (26%) | 86 (29%) |  |
 VKA | 8 (2.4%) | 4 (10%) | 4 (1.3%) |  |
 LMWH | 9 (2.7%) | 1 (2.6%) | 8 (2.7%) |  |
 DOAC | 32 (9.5%) | 1 (2.6%) | 31 (10%) |  |
 Dual Treatment | 11 (3.3%) | 1 (2.6%) | 10 (3.4%) |  |
 None | 147 (44%) | 19 (49%) | 128 (43%) |  |
 Paused | 14 (4.2%) | 0 (0%) | 14 (4.7%) |  |
 Insufficient Treatment | 19 (5.7%) | 3 (7.7%) | 16 (5.4%) |  |
HCT (%)* | 38 (6) | 33 (6) | 39 (6) | < 0.001 |
Hb (mg/dL)* | 12.87 (2.24) | 10.97 (2.12) | 13.11 (2.14) | < 0.001 |
CRP (mg/L)* | 22 (34) | 53 (52) | 18 (29) | < 0.001 |
LDH (U/L)* | 245 (109) | 336 (214) | 233 (80) | 0.003 |
INR* | 1.15 (0.26) | 1.19 (0.28) | 1.14 (0.26) | 0.062 |
PTT (sec)* | 36 (18) | 36 (10) | 36 (19) | 0.74 |
Platelets (/µL)* | 241,417 (84,297) | 230,154 (114,044) | 242,896 (79,709) | 0.25 |